BusinessKura Oncology Announces Commencement of Public Offering of Common StockBy Nasdaq OMXAug 9, 2017, 8:17 PM UTC
BusinessKura Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Tipifarnib Phase 2 StudyBy Nasdaq OMXAug 7, 2017, 8:06 PM UTC
BusinessKura Oncology to Report Second Quarter 2017 Financial ResultsBy Nasdaq OMXJul 31, 2017, 11:30 AM UTC
BusinessKura Oncology Announces Issuance of U.S. Patent for Lead Product Candidate Tipifarnib in Head and Neck CancerBy Nasdaq OMXJul 18, 2017, 11:30 AM UTC
BusinessKura Oncology Establishes Collaboration with Foundation Medicine to Support Tipifarnib Development in HRAS Mutant Head and Neck CancerBy Nasdaq OMXJul 13, 2017, 11:30 AM UTC
BusinessKura Oncology Presents Preliminary Clinical and Preclinical Data for Tipifarnib in the Treatment of Relapsed or Refractory Peripheral T-Cell LymphomaBy Nasdaq OMXJun 14, 2017, 11:30 AM UTC
BusinessKura Oncology Announces Data Presentations for Tipifarnib at the International Conference on Malignant Lymphoma and the European Hematology Association Annual MeetingBy Nasdaq OMXJun 7, 2017, 11:30 AM UTC
